This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.

Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.

Investing.com reports Perrigo (PRGO) shares rose 24.4% to $13.41 after the company posted Q2 2026 results above analyst estimates. All-in adjusted diluted EPS was $0.50 versus $0.34 expected, and revenue was about $1.02B versus $1.01B. Perrigo cited cost savings and its Three-S strategy, reaffirmed 2026 EPS guidance, and said €305.6M from the Dermacosmetics sale will aid debt reduction.

Perrigo Co. plc (PRGO) reported Q2 profit despite lower sales. Net income was $74.5M versus a $8.4M loss a year earlier. EPS was $0.53 versus a loss of $0.06. Net sales fell to $1.02B from $1.06B. Perrigo reaffirmed FY2026 outlook, with adjusted EPS of $2.00 to $2.30. Shares rose about 11% premarket to $12.

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cy26q2ex991pressrelease.htm EX-99.1 Document EXHIBIT 99.1 Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S

Perrigo Company plc (NYSE: PRGO) said its Board appointed Albert A. Manzone, a current director, as Interim President and CEO effective immediately, and launched a search for a permanent successor. Patrick Lockwood-Taylor resigned as President/CEO and from the Board, after the Board found certain personal conduct inconsistent with the company’s code of conduct. Perrigo reaffirmed its 2026 outlook: All In net sales growth of (5.5)% to (1.5)% and adjusted EPS of $2.00 to $2.30.

SentinelOne reported Q2 2026 earnings beating estimates with $0.08 adjusted EPS and $292M revenue, up 21% YoY. It raised full-year guidance, showing record 10% operating margin. Shares rose 10.73% intraday but fell 3.96% after hours.